PRIME-HCC: ipilimumab and nivolumab in liver cancer
1 Просмотры
• 06/28/23
0
0
встраивать
administrator
Подписчики
David Pinato, MD, MRes, PhD, Imperial College London, London, UK, shares an update on the Phase Ib PRIME-HCC trial (NCT03682276) of neoadjuvant ipilimumab and nivolumab before liver resection in patients with hepatocellular cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Показать больше
Комментарии Facebook
SORT BY-
Лучшие комментарии
-
Последние комментарии